January saw a series of deal announcements from diagnostic, device and biopharma companies. Bristol-Myers Squibb’s acquisition of Celgene Corp. for $74 billion is easily the best known, given that it’s the fourth-largest biopharma acquisition ever. It was far from the only important deal, however. Review this comprehensive list of deal-making activity to learn who’s acquiring, partnering with or financing whom. Gain insights into both business and clinical developments, and get a peek into the in vitro diagnostics, medical devices and pharmaceuticals pipelines. Find out which companies have settled patent litigation. Discover which two companies have inked a partnership to create gene therapies with applications for Alzheimer’s and Parkinson’s.